Xanthoangelol

Xanthoangelol

SCHEMBL454823

CC(C)=CCC/C(C)=C/Cc1c(O)ccc(C(=O)/C=C/c2ccc(O)cc2)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 1.00
LMNA P02545 2/20 1.00
MAPT P10636 2/20 1.00
MAOB P27338 2/20 1.00
KMT2A Q03164 2/20 1.00
ALDH1A1 P00352 1/20 1.00
GAA P10253 1/20 1.00
PTPN1 P18031 2/20 0.81
DHODH Q02127 1/20 0.81
MGAM O43451 1/20 0.72
CASP3 P42574 1/20 0.70
SENP8 Q96LD8 1/20 0.70
SENP7 Q9BQF6 1/20 0.70
SENP6 Q9GZR1 1/20 0.70
PTGS1 P23219 2/20 0.69
PTGS2 P35354 2/20 0.69
CYP19A1 P11511 2/20 0.60
TYR P14679 2/20 0.60
PPARG P37231 2/20 0.60
PPARA Q07869 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Xanthoangelol SCHEMBL5519362 1.00 MEN1 (1.00) MEN1LMNAMAPTMAOBKMT2A
Xanthoangelol SCHEMBL5519356 1.00 MEN1 (1.00) MEN1LMNAMAPTMAOBKMT2A
SCHEMBL5515022 0.99 MEN1 (0.98) MEN1LMNAMAPTMAOBKMT2A
SCHEMBL14523853 0.99 MEN1 (0.98) MEN1LMNAMAPTMAOBKMT2A
SCHEMBL5515052 0.92 MAOB (0.84) MEN1LMNAMAPTMAOBKMT2A
SCHEMBL5515048 0.92 MAOB (0.84) MEN1LMNAMAPTMAOBKMT2A
SCHEMBL5515045 0.92 MAOB (0.84) MEN1LMNAMAPTMAOBKMT2A
SCHEMBL14523856 0.91 MEN1 (0.84) MEN1LMNAMAPTMAOBKMT2A
SCHEMBL21716621 0.90 MAOB (0.82) MEN1LMNAMAPTMAOBKMT2A
Isobavachalcone SCHEMBL600137 0.90 PTPN1 (1.00) MEN1LMNAMAPTMAOBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102422-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-04-16 US claimed
US-20250064877-A1 COMPOSITION FOR INCREASING MUSCLE STRENGTH CONTAINING COMPLEX EXTRACT OF ANGELICA KEISKEI AND LEAVES OF MORUS ALBA L. HAMSOA PHARMACEUTICAL CO., LTD. (KR) 2025-02-27 US claimed
US-20240269210-A1 METHOD FOR ENHANCING BIOLOGICAL ENERGY WITH EXTRACT TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD. (TW) 2024-08-15 US claimed
US-20240165143-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY 2024-05-23 US claimed
WO-2024080512-A1 COMPOSITION FOR INCREASING MUSCLE STRENGTH CONTAINING COMPLEX EXTRACT OF ANGELICA KEISKEI AND LEAVES OF MORUS ALBA L. 주식회사 함소아제약 2024-04-18 WO claimed
EP-4040965-A2 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2022-08-17 EP claimed
CN-114867351-A 4' -halo-containing nucleotide and nucleoside therapeutic compositions and uses related thereto 埃默里大学 2022-08-05 CN claimed
WO-2021137913-A2 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2021-07-08 WO claimed
CN-112526023-A Method for detecting content of 4-hydroxyderricin and xanthoangelol in angelica keiskei 青岛天鼎信息科技有限公司 2021-03-19 CN claimed
WO-2020032154-A1 ACETYLCHOLINESTERASE INHIBITOR 株式会社東洋マテリアル 2020-02-13 WO claimed
EP-2249641-A1 NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES Flaxan GmbH & Co. KG (US) 2010-11-17 EP claimed
WO-2009126320-A1 XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS BETAL, LLC (US) 2009-10-15 WO claimed
WO-2009108379-A1 NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES FLAXAN GMBH & CO. KG (US) 2009-09-03 WO claimed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US claimed
CN-1816328-A Therapeutic agent TAKARA BIO INC (JP) 2006-08-09 CN claimed
EP-1666051-A2 Remedies Takara Bio, Inc. (JP) 2006-06-07 EP claimed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 EP claimed
US-20040002423-A1 Remedies TAKARA BIO INC. (JP) 2004-01-01 US claimed
CN-1422159-A Therapeutic agents TAKARA SHUZO CO (JP) 2003-06-04 CN claimed
EP-1277473-A1 REMEDIES TAKARA BIO INC. (JP) 2003-01-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102422-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO SARS1, ITK, SLC43A1 MEN1 4748/4885LMNA 1958/4885MAPT 2568/4885
US-20070092551-A1 Therapeutic agent FABP4, GPR119, IAPP MEN1 2467/4885LMNA 2982/4885MAPT 2256/4885
US-20240165143-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO PNP, PRPF4, HPRT1 MEN1 4756/4885LMNA 3012/4885MAPT 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.